1, Fellowship of the Royal College of Physicians: FRCP: 2011.
2, The Cardiff University School of Medicine: Doctor of Medicine: MD: 2006.
3, Specialist Training Authority: CCST (Neurosurgery): 2004.
4, Intercollegiate Fellowship in Neurological Surgery: FRCS (Neurosurgery): 2002.
5, Fellowship of the Royal College of Surgeons of England: FRCS (Eng.): 1998.
6, Fellowship of the Royal College of Physicians and Surgeons of Glasgow: FRCPS (Glasg.): 1998.
7, Membership of the Royal College of Physicians: MRCP (UK): 1997.
8, Degrees of Bachelor of Medicine and Bachelor of Surgery, MB. BCh.University of Wales College of Medicine 1993.
9, Intercalated Degree of Bachelor of Science, BSc, in Medical Biochemistry, FIRST CLASS with HONOURS: University of Wales College of Medicine 1990.
University of Wales College of Medicine: 1987-1993.
South Thames Specialist Registrar Training in Neurosurgery: 1998-2004
Fellow in Stereotactic and Functional Neurosurgery: Hopital Nord and INSERM U318, Grenoble, France: 2003-2004
1, Professor of Neurosurgery, Kings College London: 2014-present
2, Reader in Neurosurgery, Kings College London: 2011-14
3, Senior Lecturer in Neurosurgery, Kings College London: 2007-2011
4, Consultant Neurosurgeon with special interest in Functional Neurosurgery, Image Guided Surgery and Neuro-oncology, Kings College Hospital: 2007-present
5, Senior Lecturer in Functional Neurosurgery, The Institute of Neurology: 2004-2006
6, Consultant Neurosurgeon, National Hospital for Neurology and Neurosurgery: 2004-2006
1. British Medical Association
2. Society of British Neurological Surgeons
3. European Association of Neurosurgical Societies
4. Movement Disorder Society
5. British Neuro-Oncology Society
6. British Society of Stereotactic and Functional Neurosurgery
Bond-Solon course in Excellence in Written Evidence, London 2011
1, Functional and pain including deep brain stimulation, spinal cord stimulation, occipital nerve stimulation, neuromodulation.
2, Neuro-oncology including awake craniotomy, stereotaxy, image guidance, fluorescent guided tumour resection, radiosurgery such as cyberknife and gamma-knife.
3, Spine including lumbar and cervical degenerative disease, discectomy, laminectomy, sciatica, brachalgia
1, Lead for Neuro-Oncology, King's Health Partners
2, Lead Tumour Working Group, South East London and Kent
3, Head Neurosciences Clinical Trial Unit, King's Health Partners
4, Deputy Lead Neurosciences Research Advisory Group, King's Health Partners
5, Pathway Group Member, London Cancer Alliance
1, Functional and pain: Surgical management of movement disorders and pain, neuro-modulation, imaging and targeting of deep brain nuclei, physiology of basal ganglia and its application for optimising deep brain stimulation, non motor symptoms of Parkinson's disease, novel therapies for Parkinson's disease including the role of growth factors, surgery for psychiatric disorders
2, Neuro-oncology:Surgical management of brain tumours and novel techniques, awake craniotomies, new therapies for brain tumours including immunotherapy and vaccination, genetics of brain tumours, imaging of brain tumours especially of low grade gliomas and metabolic imaging, molecular pathology of tumours
3, General: Patient reported outcome measures, clinical trials
1, Klingelhoefer L, Samuel M, Chaudhuri R, Ashkan K. An update of the impact of deep brain stimulation on non motor symptoms in Parkinson's disease. Journal of Parkinsons Disease. 2014;4(2):289-300.
2, Polyzoidis S, Ashkan K. Dendritic cell immunotherapy for glioblastoma. Expert Rev Anticancer Ther. 2014;14(7):761-3.
3, Yágüez L, Costello A, Moriarty J, Hulse N, Selway R, Clough C, Samuel M, Ashkan K. Cognitive predictors of cognitive change following bilateral subthalamic nucleus deep brain stimulation in Parkinson’s disease. Journal of Clinical Neuroscience. 2014;21(3):445-50.
4, Laxton R, Jones C, Doey L, Teelock N, Popov S, Jury A, Bhangoo R, Gullan R, Chandler C, Brazil L, Sadler G, Beaney R, Sibtain N, King A, Bodi I, Ashkan K (joint last author), Al-Sarraj S. Primary glioblastoma with oilgodendroglial differentiation has better clinical outcome but no difference in common biological markers compared with other types of glioblastoma. Neuro-Oncology. 2013;15(12):1635-43.
5, Ashkan K, Shotbolt P, David A, Samuel M. Deep brain stimulation: a return journey from psychiatry to neurology. Postgraduate Medical Journal. 2013;89(1052):323-8.
Understanding activity pie charts
What does the Consultant activity pie chart show?
The Consultant activity pie charts represent the total number of elective (planned) finished consultant episodes (FCEs) and non-elective (emergency) finished consultant episodes. A finished consultant episode usually represents the care of a single patient from admission to discharge.
Please note that for Consultants who provide both adult services for patients older than 17 years and paediatric services for patients 16 years old and younger there are two outcome reports.
Understanding mortality funnel plot charts
What does the Consultant funnel plot chart show?
The Hospital Consultant mortality funnel plot represent the total number of elective (planned) finished consultant episodes (FCEs) and non-elective (emergency) finished consultant episodes. A finished consultant episode usually represents the care of a single patient from admission to discharge.
The mortality presented here is for three years: April 2014 – March 2017. Please note that for Consultant who provide both adult services for patients older than 17 years and paediatric services for patients 16 years old and younger there are two outcome reports.
The horizontal yellow line represents the national average mortality. The solid black lines above and below the yellow line are the control limits. The upper control limit represents the highest expected mortality rate. The Consultant's outcome is highlighted in magenta.